CA3250945A1 - TRICYCLIC PARP1 INHIBITORS AND THEIR USES - Google Patents
TRICYCLIC PARP1 INHIBITORS AND THEIR USESInfo
- Publication number
- CA3250945A1 CA3250945A1 CA3250945A CA3250945A CA3250945A1 CA 3250945 A1 CA3250945 A1 CA 3250945A1 CA 3250945 A CA3250945 A CA 3250945A CA 3250945 A CA3250945 A CA 3250945A CA 3250945 A1 CA3250945 A1 CA 3250945A1
- Authority
- CA
- Canada
- Prior art keywords
- tricyclic
- parp1 inhibitors
- parp1
- inhibitors
- tricyclic parp1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263336078P | 2022-04-28 | 2022-04-28 | |
| US63/336,078 | 2022-04-28 | ||
| US202263381482P | 2022-10-28 | 2022-10-28 | |
| US63/381,482 | 2022-10-28 | ||
| PCT/US2023/020235 WO2023212219A1 (en) | 2022-04-28 | 2023-04-27 | Tricyclic parp1 inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3250945A1 true CA3250945A1 (en) | 2023-11-02 |
Family
ID=88420972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3250945A Pending CA3250945A1 (en) | 2022-04-28 | 2023-04-27 | TRICYCLIC PARP1 INHIBITORS AND THEIR USES |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11795173B1 (https=) |
| EP (3) | EP4620472A3 (https=) |
| JP (2) | JP7728989B2 (https=) |
| KR (2) | KR20260004578A (https=) |
| CN (1) | CN119173516A (https=) |
| AU (2) | AU2023259236B2 (https=) |
| CA (1) | CA3250945A1 (https=) |
| CL (2) | CL2024003262A1 (https=) |
| CO (1) | CO2024014603A2 (https=) |
| CR (1) | CR20240461A (https=) |
| DK (2) | DK4355749T3 (https=) |
| DO (1) | DOP2024000218A (https=) |
| ES (2) | ES3050217T3 (https=) |
| FI (2) | FI4497438T3 (https=) |
| HR (2) | HRP20250969T1 (https=) |
| HU (1) | HUE072274T2 (https=) |
| IL (1) | IL316278A (https=) |
| LT (2) | LT4355749T (https=) |
| MX (2) | MX2025008920A (https=) |
| NZ (1) | NZ815323A (https=) |
| PL (2) | PL4497438T3 (https=) |
| PT (2) | PT4355749T (https=) |
| SI (2) | SI4497438T1 (https=) |
| TW (2) | TWI891000B (https=) |
| WO (1) | WO2023212219A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022334408A1 (en) * | 2021-08-27 | 2024-02-15 | Impact Therapeutics (Shanghai), Inc. | Substituted tricyclic compounds as parp inhibitors and use thereof |
| AU2023209820B2 (en) | 2022-01-21 | 2024-10-10 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| IL315586A (en) * | 2022-03-11 | 2024-11-01 | Impact Therapeutics Shanghai Inc | Substituted tricyclic compounds as parp inhibitors and the use thereof |
| KR20240161147A (ko) | 2022-03-14 | 2024-11-12 | 슬랩 파마슈티컬스 엘엘씨 | 다중 사이클릭 화합물 |
| FI4497438T3 (fi) | 2022-04-28 | 2025-10-20 | Xinthera Inc | Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja |
| CN117263943A (zh) * | 2022-09-09 | 2023-12-22 | 轩竹生物科技股份有限公司 | 聚（adp核糖）聚合酶选择性抑制剂 |
| JP2025538192A (ja) * | 2022-11-10 | 2025-11-26 | 上海海和薬物研究開発股▲ふん▼有限公司 | 縮合三環式ｐａｒｐ１阻害剤、その調製方法、および使用 |
| TW202525808A (zh) * | 2023-09-13 | 2025-07-01 | 大陸商上海瑛派藥業有限公司 | 用作ｐａｒｐ１抑制劑的化合物、其用途及包含其之組合物 |
| AU2024359243A1 (en) * | 2023-10-09 | 2026-04-23 | Incyte Corporation | Processes for preparing kras inhibitors |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPS137402A0 (en) | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| US8404713B2 (en) | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| WO2009076512A1 (en) | 2007-12-11 | 2009-06-18 | Epix Delaware, Inc. | Carboxamidξ compounds and their use as chemokine receptor agonists |
| KR101779137B1 (ko) | 2009-01-23 | 2017-09-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 폴리(ａｄｐ-리보스)폴리머라제(ｐａｒｐ) 억제제 |
| EP2459561A1 (en) | 2009-07-30 | 2012-06-06 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
| CA2774266A1 (en) | 2009-09-16 | 2011-03-24 | Cylene Pharmaceuticals, Inc. | Novel tricyclic protein kinase modulators |
| HUE051078T2 (hu) | 2012-10-26 | 2021-03-01 | Nerviano Medical Sciences Srl | 4-karboxamido-izoindolinone származék mint szelektív parp-1 inhibitor |
| CN104370898A (zh) | 2013-08-14 | 2015-02-25 | 黄传满 | 咪唑并[1,2-a]吡啶类化合物及其制备方法和用途 |
| JP2017508798A (ja) | 2014-03-07 | 2017-03-30 | ザ ジョンズ ホプキンス ユニバーシティ | ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤 |
| CN105753814A (zh) | 2015-01-01 | 2016-07-13 | 成都贝斯凯瑞生物科技有限公司 | 取代氮杂环衍生物及其应用 |
| PH12017502228B1 (en) | 2015-06-09 | 2022-08-03 | Onconic Therapeutics Inc | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same |
| MA42659A (fr) | 2015-08-17 | 2018-06-27 | Lupin Ltd | Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp |
| EA201992781A1 (ru) | 2017-05-22 | 2020-04-01 | Эмджен Инк. | Ингибиторы g12c kras и способы их применения |
| IL283127B1 (en) | 2018-11-14 | 2026-02-01 | Smilebiotek Zhuhai Ltd | Animal-based models, scanning methods, and methods of treating intraocular diseases or disorders |
| MX2022000711A (es) | 2019-07-19 | 2022-02-23 | Astrazeneca Ab | Inhibidores de parp1. |
| US12459899B2 (en) | 2019-10-30 | 2025-11-04 | DIGMBIO, Inc. | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient |
| US11795158B2 (en) * | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| TW202309025A (zh) | 2021-04-19 | 2023-03-01 | 美商辛瑟拉股份有限公司 | Parp1抑制劑及其用途 |
| CA3213029A1 (en) | 2021-04-22 | 2022-10-27 | Yuli Xie | Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof |
| WO2022223025A1 (zh) | 2021-04-23 | 2022-10-27 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| WO2022222965A1 (zh) | 2021-04-23 | 2022-10-27 | 成都百裕制药股份有限公司 | 吡啶衍生物及其在医药上的应用 |
| TW202304911A (zh) | 2021-04-23 | 2023-02-01 | 大陸商南京明德新藥研發有限公司 | 吡啶醯胺類化合物 |
| WO2022222966A1 (zh) | 2021-04-23 | 2022-10-27 | 成都百裕制药股份有限公司 | 一种选择性parp1抑制剂及其应用 |
| WO2022228387A1 (en) | 2021-04-26 | 2022-11-03 | Fochon Biosciences, Ltd. | Compounds as parp inhibitors |
| EP4349836A4 (en) | 2021-05-24 | 2024-10-30 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, ITS PREPARATION METHOD AND ITS APPLICATION IN DRUGS |
| CN115403595A (zh) | 2021-05-27 | 2022-11-29 | 江苏恒瑞医药股份有限公司 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
| JP2024522736A (ja) | 2021-06-16 | 2024-06-21 | リペア セラピューティクス インコーポレイテッド | がん治療のためのｐａｒｐ阻害剤と組み合わせたａｔｒ阻害剤の使用 |
| AU2022334408A1 (en) * | 2021-08-27 | 2024-02-15 | Impact Therapeutics (Shanghai), Inc. | Substituted tricyclic compounds as parp inhibitors and use thereof |
| CN118119618A (zh) | 2021-09-09 | 2024-05-31 | 南京奥利墨斯医药科技有限公司 | 一种杂芳环类化合物及其应用 |
| WO2023046034A1 (zh) | 2021-09-22 | 2023-03-30 | 明慧医药（杭州）有限公司 | 一种含氮杂环化合物、其制备方法、其中间体及其应用 |
| WO2023046149A1 (zh) | 2021-09-26 | 2023-03-30 | 张文燕 | 喹喔啉类化合物及其医药用途 |
| WO2023046158A1 (zh) | 2021-09-26 | 2023-03-30 | 张文燕 | 氮杂喹啉酮类化合物及其医药用途 |
| WO2023051716A1 (zh) | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 杂芳基衍生物parp抑制剂及其用途 |
| WO2023051812A1 (zh) | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 含氮杂环衍生物parp抑制剂及其用途 |
| US20240391937A1 (en) | 2021-09-30 | 2024-11-28 | Xizang Haisco Pharmaceutical Co., Ltd. | Bicyclic derivative parp inhibitor and use thereof |
| US20230159525A1 (en) | 2021-10-01 | 2023-05-25 | Xinthera, Inc. | Azetidine and pyrrolidine parp1 inhibitors and uses thereof |
| WO2023061406A1 (zh) | 2021-10-12 | 2023-04-20 | 微境生物医药科技(上海)有限公司 | 含三并环结构的parp抑制剂、及其制备方法和医药用途 |
| JP7762306B2 (ja) | 2021-11-19 | 2025-10-29 | 康百達（四川）生物医薬科技有限公司 | 選択的ｐａｒｐ１阻害剤およびその用途 |
| CN116143776A (zh) | 2021-11-22 | 2023-05-23 | 南京圣和药业股份有限公司 | Parp1抑制剂及其应用 |
| CA3241338A1 (en) | 2021-12-17 | 2023-06-22 | Yongqi Deng | Parp inhibitor, pharmaceutical composition comprising same, and use thereof |
| WO2023133413A1 (en) | 2022-01-07 | 2023-07-13 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| WO2023134647A1 (zh) | 2022-01-13 | 2023-07-20 | 优领医药科技(香港)有限公司 | 含哌嗪并环类衍生物、其药学上可接受的盐及其制备方法和应用 |
| WO2023138541A1 (zh) | 2022-01-20 | 2023-07-27 | 微境生物医药科技(上海)有限公司 | 吡啶酰胺类parp抑制剂、及其制备方法和医药用途 |
| AU2023209820B2 (en) | 2022-01-21 | 2024-10-10 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| CN116535401A (zh) | 2022-01-25 | 2023-08-04 | 南京圣和药业股份有限公司 | 新的parp1抑制剂及其应用 |
| WO2023143236A1 (zh) | 2022-01-26 | 2023-08-03 | 中国药科大学 | 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用 |
| WO2023147009A1 (en) | 2022-01-27 | 2023-08-03 | The Johns Hopkins University | Clinical-grade therapeutic progenitors generated from tankyrase/parp-inhibited pluripotent stem cell banks |
| US20260098024A1 (en) | 2022-01-27 | 2026-04-09 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| US20250177359A1 (en) | 2022-01-28 | 2025-06-05 | Oulun Yliopisto | Compounds for use in the treatment of cancer and inflammatory conditions |
| KR20230116457A (ko) | 2022-01-28 | 2023-08-04 | 경북대학교 산학협력단 | 작약 추출물을 포함하는 만성폐쇄성폐질환 예방 또는 치료용 약학적 조성물 |
| WO2023146960A1 (en) | 2022-01-28 | 2023-08-03 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| KR20240149429A (ko) | 2022-02-16 | 2024-10-14 | 듀크 스트리트 바이오 리미티드 | 약학적 화합물 |
| IL315586A (en) * | 2022-03-11 | 2024-11-01 | Impact Therapeutics Shanghai Inc | Substituted tricyclic compounds as parp inhibitors and the use thereof |
| FI4497438T3 (fi) | 2022-04-28 | 2025-10-20 | Xinthera Inc | Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja |
| WO2023207284A1 (en) | 2022-04-28 | 2023-11-02 | Ningbo Newbay Technology Development Co., Ltd | Piperazine derivatives as parp1 inhibitiors |
| EP4514795A4 (en) | 2022-04-28 | 2025-12-31 | Ningbo Newbay Tech Development Co Ltd | COMPOUNDS USED AS PARP1 INHIBITORS |
| CN119110801A (zh) | 2022-05-07 | 2024-12-10 | 南京明德新药研发有限公司 | 选择性抑制parp1的氟代喹喔啉酮衍生物 |
| CN119255995A (zh) | 2022-05-25 | 2025-01-03 | 西藏海思科制药有限公司 | 双环衍生物parp抑制剂及其用途 |
| US20250346573A1 (en) | 2022-06-02 | 2025-11-13 | Chengdu Easton Biopharmaceuticals Co., Ltd. | Azaquinolinone derivative, preparation method therefor and use thereof |
| CN117447449A (zh) | 2022-07-13 | 2024-01-26 | 南京圣和药业股份有限公司 | Parp1抑制剂及其应用 |
| CN115232129B (zh) * | 2022-08-18 | 2023-12-01 | 上海闻耐医药科技有限公司 | 一种parp1选择性抑制剂及其制备方法和用途 |
| WO2024041643A1 (zh) | 2022-08-25 | 2024-02-29 | 江苏恒瑞医药股份有限公司 | 稠合三环类化合物、其制备方法及其在医药上的应用 |
| US20240132449A1 (en) | 2022-08-30 | 2024-04-25 | 1Cbio, Inc. | Heterocyclic compounds and methods of use thereof |
| CN119365468A (zh) | 2022-08-31 | 2025-01-24 | 江苏恒瑞医药股份有限公司 | 稠合二环类化合物、其制备方法及其在医药上的应用 |
| CN117658983A (zh) | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
| TW202416977A (zh) | 2022-09-30 | 2024-05-01 | 大陸商中國醫藥研究開發中心有限公司 | 含氮雜環類化合物及其醫藥用途 |
| TW202415658A (zh) | 2022-09-30 | 2024-04-16 | 大陸商中國醫藥研究開發中心有限公司 | 含氮雜環類化合物及其醫藥用途 |
| US20240174669A1 (en) | 2022-10-06 | 2024-05-30 | Xinthera, Inc. | Crystalline forms of a parp1 inhibitor |
| WO2024083201A1 (zh) | 2022-10-20 | 2024-04-25 | 成都赜灵生物医药科技有限公司 | 并杂环类化合物及其用途 |
| CN117946074A (zh) | 2022-10-20 | 2024-04-30 | 上海海和药物研究开发股份有限公司 | 具有parp1抑制活性的化合物及其用途 |
| CN120035592A (zh) | 2022-10-20 | 2025-05-23 | 成都赜灵生物医药科技有限公司 | 并杂环类氘代化合物及其用途 |
| WO2024083218A1 (zh) | 2022-10-20 | 2024-04-25 | 成都赜灵生物医药科技有限公司 | 取代四氢吡啶类化合物及其用途 |
| EP4615581A2 (en) | 2022-11-09 | 2025-09-17 | Laekna Pharmaceutical Ningbo Co., Ltd. | Fused multicyclic compounds and their use as parp1 inhibitors |
| JP2025538192A (ja) | 2022-11-10 | 2025-11-26 | 上海海和薬物研究開発股▲ふん▼有限公司 | 縮合三環式ｐａｒｐ１阻害剤、その調製方法、および使用 |
| CN120035596A (zh) | 2022-11-23 | 2025-05-23 | 江苏恒瑞医药股份有限公司 | 一种含氮杂环类化合物的可药用盐、晶型及制备方法 |
| CN118084916A (zh) | 2022-11-25 | 2024-05-28 | 成都赜灵生物医药科技有限公司 | 三并杂环类化合物及其用途 |
| CN120882710A (zh) | 2023-03-24 | 2025-10-31 | 新特拉有限公司 | 氮杂环丁烷parp1抑制剂的结晶形式 |
| CN116987066B (zh) | 2023-06-20 | 2025-07-25 | 四川大学 | 一种嘧啶类化合物及其制备方法和应用 |
| CN117017962A (zh) | 2023-08-23 | 2023-11-10 | 复旦大学附属肿瘤医院 | 一种hdaci抑制剂在制备治疗卵巢癌药物中的用途 |
-
2023
- 2023-04-27 FI FIEP24217893.7T patent/FI4497438T3/fi active
- 2023-04-27 PL PL24217893.7T patent/PL4497438T3/pl unknown
- 2023-04-27 US US18/140,370 patent/US11795173B1/en active Active
- 2023-04-27 SI SI202330046T patent/SI4497438T1/sl unknown
- 2023-04-27 HU HUE23797297A patent/HUE072274T2/hu unknown
- 2023-04-27 AU AU2023259236A patent/AU2023259236B2/en active Active
- 2023-04-27 NZ NZ815323A patent/NZ815323A/en unknown
- 2023-04-27 HR HRP20250969TT patent/HRP20250969T1/hr unknown
- 2023-04-27 CA CA3250945A patent/CA3250945A1/en active Pending
- 2023-04-27 CR CR20240461A patent/CR20240461A/es unknown
- 2023-04-27 CN CN202380036872.0A patent/CN119173516A/zh active Pending
- 2023-04-27 EP EP25180004.1A patent/EP4620472A3/en active Pending
- 2023-04-27 HR HRP20251173TT patent/HRP20251173T1/hr unknown
- 2023-04-27 ES ES24217893T patent/ES3050217T3/es active Active
- 2023-04-27 TW TW112115680A patent/TWI891000B/zh active
- 2023-04-27 WO PCT/US2023/020235 patent/WO2023212219A1/en not_active Ceased
- 2023-04-27 SI SI202330037T patent/SI4355749T1/sl unknown
- 2023-04-27 FI FIEP23797297.1T patent/FI4355749T3/fi active
- 2023-04-27 EP EP23797297.1A patent/EP4355749B1/en active Active
- 2023-04-27 EP EP24217893.7A patent/EP4497438B1/en active Active
- 2023-04-27 ES ES23797297T patent/ES3038967T3/es active Active
- 2023-04-27 DK DK23797297.1T patent/DK4355749T3/da active
- 2023-04-27 JP JP2024563302A patent/JP7728989B2/ja active Active
- 2023-04-27 LT LTEPPCT/US2023/020235T patent/LT4355749T/lt unknown
- 2023-04-27 PL PL23797297.1T patent/PL4355749T3/pl unknown
- 2023-04-27 PT PT237972971T patent/PT4355749T/pt unknown
- 2023-04-27 IL IL316278A patent/IL316278A/en unknown
- 2023-04-27 PT PT242178937T patent/PT4497438T/pt unknown
- 2023-04-27 LT LTEP24217893.7T patent/LT4497438T/lt unknown
- 2023-04-27 KR KR1020257042273A patent/KR20260004578A/ko active Pending
- 2023-04-27 KR KR1020247039178A patent/KR102903399B1/ko active Active
- 2023-04-27 DK DK24217893.7T patent/DK4497438T3/da active
- 2023-04-27 TW TW114123039A patent/TW202540112A/zh unknown
- 2023-09-20 US US18/471,250 patent/US12006322B2/en active Active
-
2024
- 2024-05-02 US US18/653,538 patent/US12421241B2/en active Active
- 2024-10-25 DO DO2024000218A patent/DOP2024000218A/es unknown
- 2024-10-25 CL CL2024003262A patent/CL2024003262A1/es unknown
- 2024-10-25 MX MX2025008920A patent/MX2025008920A/es unknown
- 2024-10-25 CO CONC2024/0014603A patent/CO2024014603A2/es unknown
- 2024-10-25 MX MX2024013195A patent/MX2024013195A/es unknown
-
2025
- 2025-04-08 AU AU2025202495A patent/AU2025202495A1/en active Pending
- 2025-08-13 JP JP2025134784A patent/JP2025161856A/ja active Pending
- 2025-08-25 CL CL2025002554A patent/CL2025002554A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3250945A1 (en) | TRICYCLIC PARP1 INHIBITORS AND THEIR USES | |
| CA3249318A1 (en) | PARP1 INHIBITORS AND THEIR USES | |
| EP4469449A4 (en) | PARP1 INHIBITORS AND THEIR USES | |
| AU2024325407A1 (en) | Benzopyridinones and benzopyrimidinones as pi3k inhibitors | |
| IL320829A (en) | PARP1 inhibitors and their uses | |
| AU2024314618A1 (en) | Pi3k inhibitors and use thereof | |
| EP4338737A4 (en) | PARP7 INHIBITOR AND ITS USE | |
| HK40124295A (en) | Tricyclic parp1 inhibitors and uses thereof | |
| HK40124295B (en) | Tricyclic parp1 inhibitors and uses thereof | |
| EP4330228A4 (en) | G-ALPHA-S INHIBITORS AND USES THEREOF | |
| HK40119206A (en) | Parp1 inhibitors and uses thereof | |
| HK40120613A (en) | Parp1 inhibitors and uses thereof | |
| HK40119802A (en) | Parp1 inhibitors and uses thereof | |
| HK40107117A (en) | Parp1 inhibitors and uses thereof | |
| HK40126028A (en) | Tyk2 inhibitors and uses thereof | |
| HK40121749A (en) | Tyk2 inhibitors and uses thereof | |
| HK40121455A (en) | Tyk2 inhibitors and uses thereof | |
| HK40105811A (en) | Tyk2 inhibitors and uses thereof | |
| HK40105297A (zh) | Tyk2抑制剂及其用途 | |
| HK40105803A (en) | Tyk2 inhibitors and uses thereof | |
| CA3299252A1 (en) | Trim7 inhibitors and uses thereof | |
| CA3299235A1 (en) | Trim7 inhibitors and uses thereof | |
| CA3277886A1 (en) | Parp1 inhibitors | |
| HK40114337A (en) | Irhom2 inhibitors and uses thereof | |
| HK40108347A (en) | Inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241028 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20241028 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241028 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241030 |
|
| D16 | Fast track examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D16-D106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION REQUESTED - PARAGRAPH 84(1)(A) OF THE PATENT RULES Effective date: 20241030 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241030 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241030 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250131 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250131 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250131 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250131 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250217 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250305 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250305 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250305 |
|
| D17 | Fast track examination accepted |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D17-D110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION DETERMINED COMPLIANT - PARAGRAPH 84(1)(A) OF THE PATENT RULES Effective date: 20250314 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250314 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250417 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250422 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250422 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250428 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250428 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250505 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250526 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251208 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260303 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260303 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260306 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260320 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260407 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260407 |